OverviewSuggest Edit

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to treat life-threatening illnesses. The Company's purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Each polymer bead contains millions of pores and channels that can be modified to remove substances as small as drugs, to substances as large as antibodies.
TypePublic
Founded2002
HQSouth Brunswick Township, US
Websitecytosorbents.com

Latest Updates

Employees (est.) (Sept 2017)65
Revenue (FY, 2017)$15.2 M(+60%)
Share Price (Nov 2020)$8.8 (+2%)
Cybersecurity ratingAMore

Key People/Management at Cytosorbents

Phillip P. Chan

Phillip P. Chan

Chief Executive Officer and President
Alan D. Sobel

Alan D. Sobel

Director
Kathleen Bloch

Kathleen Bloch

Chief Financial Officer
Vincent Capponi

Vincent Capponi

Chief Operating Officer
Show more

Cytosorbents Office Locations

Cytosorbents has offices in South Brunswick Township and Berlin
South Brunswick Township, US (HQ)
7 Deerpark Dr, Monmouth Junction
Berlin, DE
Müggelseedamm 131
Show all (2)

Cytosorbents Financials and Metrics

Cytosorbents Revenue

Embed Graph
View revenue for all periods
Cytosorbents's revenue was reported to be $15.15 m in FY, 2017 which is a 59% increase from the previous period.
USD

Revenue (FY, 2017)

15.2m

Revenue growth (FY, 2016 - FY, 2017), %

59%

Gross profit (FY, 2017)

9.6m

Gross profit margin (FY, 2017), %

63.6%

Net income (FY, 2017)

(8.5m)

EBIT (FY, 2017)

(9.8m)

Market capitalization (17-Nov-2020)

378.7m

Closing stock price (17-Nov-2020)

8.8

Cash (31-Dec-2017)

17.3m

EV

371.3m
Cytosorbents's current market capitalization is $378.7 m.
USDFY, 2015FY, 2016FY, 2017

Revenue

4.8m9.5m15.2m

Revenue growth, %

99%59%

Cost of goods sold

2.2m4.0m5.5m

Gross profit

2.6m5.6m9.6m
USDFY, 2015FY, 2016FY, 2017

Cash

5.3m5.2m17.3m

Accounts Receivable

648.9k1.4m2.2m

Prepaid Expenses

511.9k315.8k416.0k

Inventories

1.2m834.0k795.7k
USDFY, 2015FY, 2016FY, 2017

Net Income

(8.1m)(11.8m)(8.5m)

Depreciation and Amortization

113.0k161.6k218.3k

Inventories

(671.3k)340.4k57.3k

Accounts Payable

(83.2k)2.1m523.4k
USDFY, 2015

Financial Leverage

1.4 x
Show all financial metrics

Cytosorbents Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Cytosorbents Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Cytosorbents Online and Social Media Presence

Embed Graph

Cytosorbents News and Updates

CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference

MONMOUTH JUNCTION, N.J., Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world,...

CytoSorbents Reports Record Third Quarter 2020 Financial Results

MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its...

CytoSorbents Partners with InvoSurg and Surgical Partners to Commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under FDA Emergency Use Authorization for COVID-19

MONMOUTH JUNCTION, N.J., Aug. 17, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO) has entered into separate agreements with InvoSurg Inc. and Surgical Partners to commercialize CytoSorb® under its FDA Emergency Use Authorization (EUA) in adult, critically-ill, COVID-19...

CytoSorbents Achieves Milestone of More than 100,000 CytoSorb Treatments Delivered Cumulatively To Date

MONMOUTH JUNCTION, N.J., Aug. 3, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces...

CytoSorbents Awarded $4.4 Million Contract by the U.S. Department of Defense to Complete HemoDefend-BGA Adsorber Preclinical Development

MONMOUTH JUNCTION, N.J., July 31, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader specializing in blood purification, announced today that the Assistant Secretary of Defense for Health Affairs, endorsed by the Department of Defense office...

CytoSorbents Corporation Announces Pricing of $50 Million Public Offering of Common Stock

MONMOUTH JUNCTION, N.J., July 22, 2020 /PRNewswire/ -- CytoSorbents Corporation (Nasdaq: CTSO) (the "Company"), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac...
Show more

Cytosorbents Blogs

Terumo Cardiovascular and CytoSorbents Collaborate to Commercialize CytoSorb® in Ten U.S. Hotspot States under Emergency Use Authorization for COVID-19

ANN ARBOR, Mich. and MONMOUTH JUNCTION, N.J., Aug. 24, 2020 /PRNewswire/ — Terumo Cardiovascular, a global leader in cardiovascular surgery technologies and subsidiary of Japan-based Terumo Corporation (TSE: 4543), and CytoSorbents Corporation (NASDAQ: CTSO), manufacturer of the CytoSorb® extracorpo…

CytoSorbents Reports Record Second Quarter 2020 Financial Results

CytoSorbents posts record Q2 2020 Total Revenue of $9.8 million, including a 61% increase in Product Sales to $9.5 million, with $30 million in trailing 12-month Product Sales MONMOUTH JUNCTION, N.J., Aug. 4, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy …

CytoSorbents Announces the REFRESH 2-AKI Trial Data Monitoring Committee Has Recommended Study Resumption Following Favorable Review of Safety Data

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ — CytoSorbents Corporation (Nasdaq: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patients around the wo…

CytoSorbents to Report Q2 2020 Operating and Financial Results

MONMOUTH JUNCTION, N.J., July 28, 2020 /PRNewswire/ — CytoSorbents Corporation (CTSO),  CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around…

CytoSorbents Provides Preliminary Q2 2020 Financial Results and Corporate Update

Achieved preliminary record total quarterly revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a treatment of cytokine storm in COVID-19 infection and other illnesses. MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ — CytoSorbents Corporation (NASDAQ:CTSO…

CytoSorbents Corporation Announces Proposed $40 Million Public Offering of Common Stock

MONMOUTH JUNCTION, N.J., July 20, 2020 /PRNewswire/ — CytoSorbents Corporation (Nasdaq: CTSO) (the “Company”) a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat cytokine storm and deadly inflammation in critically-ill and cardiac surgery patient…
Show more

Cytosorbents Frequently Asked Questions

  • When was Cytosorbents founded?

    Cytosorbents was founded in 2002.

  • Who are Cytosorbents key executives?

    Cytosorbents's key executives are Phillip P. Chan, Alan D. Sobel and Kathleen Bloch.

  • How many employees does Cytosorbents have?

    Cytosorbents has 65 employees.

  • What is Cytosorbents revenue?

    Latest Cytosorbents annual revenue is $15.2 m.

  • What is Cytosorbents revenue per employee?

    Latest Cytosorbents revenue per employee is $233.1 k.

  • Who are Cytosorbents competitors?

    Competitors of Cytosorbents include Apollo Endosurgery, Noxilizer and Nephros.

  • Where is Cytosorbents headquarters?

    Cytosorbents headquarters is located at 7 Deerpark Dr, Monmouth Junction, South Brunswick Township.

  • Where are Cytosorbents offices?

    Cytosorbents has offices in South Brunswick Township and Berlin.

  • How many offices does Cytosorbents have?

    Cytosorbents has 2 offices.